AdAlta Ltd

This week we will join the The Stock Network ASX Gems investment conference to outline the value of our “East to West” cell therapy and AD-214 fibrosis strategies???Register and watch for free on Friday 28 March:?https://lnkd.in/gYFQte9G

AdAlta is thrilled to announce the first external party-sourced investment in its “East to West” cellular immunotherapy strategy. It will see SYNthesis BioVentures, a venture capital fund focused on early-stage therapeutics, invest up to A$2M in AdCella Pty Ltd, which AdAlta specifically created to execute its “East to West” growth initiative. On top of this initial investment of up to A$2M, SYNthesis BioVentures also has the opportunity to further increase its exposure to AdAlta’s “East to West” strategic initiative via a right to invest A$5.5 million in the now launched AdCella Series A funding round. Importantly, SYNthesis is so much more than just a source of funding for AdAlta’s AdCella business. SYNthesis has already provided, and will continue to provide, valuable feedback on AdCella’s asset selection deliberations and cross border transaction tactics. This seed financing of up to A$2M being provided by SYNthesis BioVentures will fund accelerated planning and preparation work for the three recently announced cellular immunotherapy assets now being considered for licensing by AdCella. The bottom line here is that the bankrolling of AdCella’s growth will not be reliant on further funding from AdAlta. And going forward, revenues AdAlta derives from its stake in AdCella will be diverse. They will include so much more than just revenues flowing from on-licensing agreements of AdCella drug candidates. They will also consist of management fees and performance incentives for services provided to this business. We look forward to making further announcements over coming months that highlight our success in creating a sustainable business model that provides a bridge between Asian biotech innovation and the West’s biopharma sector. ASX announcement: https://lnkd.in/gN3SkF-G

AdAlta (ASX:1AD) Managing Director and CEO Dr Tim Oldham, said IPF is classed as a rare disease but one that impacts far more patients than that classification would suggest. “There are half a million patients living under this death sentence of IPF around the world today,” - The Australian reports | Read more:?https://lnkd.in/gKQSAeeA

AdAlta (ASX:1AD) receives $0.42m advance on its FY25 R&D Tax Incentive rebate. These new funds will help support due diligence and definitive agreements for ”East to West” cellular immunotherapy assets. ?“Gaining early access to a portion of our FY25 R&D Tax Incentive rebate via this loan facility with Radium Capital is a sensible cash flow management initiative. These additional funds will immediately be put to good use, providing finance to accelerate due diligence and definitive agreements for the three products now under exclusive negotiation rights under our “East-to-West” growth strategy”. - Tim Oldham, AdAlta CEO & Managing Director ASX announcement:?https://lnkd.in/geZ-S9zp

AdAlta is thrilled to be presenting at the upcoming 4th BioCentury-BayHelix East-West Biopharma Summit in Singapore which will take place 4-5 March 2025. The Summit will be another great opportunity for AdAlta’s leadership team to showcase to investors how the company is combining Asia's innovation in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem. In the process, AdAlta is creating a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients. Attendees at the 4th BioCentury-BayHelix East-West Biopharma Summit will also hear how the growth upside in AdAlta’s “East to West” growth strategy is already starting to kick some goals, with three term sheets now in advanced due diligence – and many more in an ever-lengthening pipe-line. For more information visit:?https://lnkd.in/g_p36n9f

AdAlta’s decision to accelerate the implementation of its “East to West” strategy, which is seeing the company focus on licensing cell therapy products from Asia (China especially) for Western markets has received BIOSHARES’ tick of approval. The respected biotech investment site highlights the factors driving the strategy, including the high number and quality of T-cell therapies being developed in China now wanting an entrée into Western markets, and the skill sets of both AdAlta’s highly experienced leadership team and its collaborating partner, Synthesis Bioventures. BIOSHARES succinctly explains how cell therapy assets identified by AdAlta are progressing through due diligence process and how AdAlta business unit AdCella will raise the funds to conduct drug candidate development works. AdAlta anticipates three to six venture capital investors will participate in the first outside funding round of AdCella. BIOSHARES has a favourable view on AdAlta’s “East to West” strategy, issuing a Speculative Buy Class B recommendation on the company. Read more:?https://lnkd.in/g4zCV2Mq

AdAlta (ASX:1AD) hosted an investor webinar on Tuesday 11 February 2025. The webinar presented by AdAlta’s Chief Executive Officer & Managing Director, Dr Tim Oldham. In the webinar Dr Oldham discussed the results of AdAlta’s strategic review and portfolio prioritization and key highlights follow: - What drives AdAlta’s “East to West” cellular immunotherapy strategy - How the “East to West” strategy will be AdAlta’s key driver of future pipeline growth and value creation - Recent progress made in executing the “East to West” strategy, including the signing of term sheets - How the value inherent in AdAlta’s fibrosis disease drug candidate AD-214 will be monetised Investor presentation:?https://lnkd.in/gAWWBxFE Watch the presentation here:?https://lnkd.in/g9dCmbeX

Stockhead’s Fraser Palamara chats with AdAlta Ltd (ASX:1AD) CEO & Managing Director Tim Oldham about the Company’s “East to West” strategy that leverages the incredible innovation coming out of Asia generally and China especially, in the rapidly growing cellular immunotherapies market segment. Hear how the strategy is giving AdAlta a foothold in ground-breaking T-cell therapies in solid cancers, and more. Watch the interview here:?https://lnkd.in/gZ8am3AN

"AdAlta has ranked its East to West cellular immunotherapy strategy as its core growth priority, saying that it is the key driver of future pipeline growth and value creation, the company has executed two non-binding term sheets to in-licence clinical stage CAR-T products, bringing total products in advanced, exclusive due diligence to three" - Stockhead | Read more:?https://lnkd.in/gzwUDBuw

AdAlta Limited (ASX:1AD) will host an investor webinar on Tuesday 11 February 2025. The webinar will be presented by AdAlta’s Chief Executive Officer & Managing Director, Dr Tim Oldham.?In the webinar Dr Oldham will discuss?the results of AdAlta’s strategic review and portfolio prioritization and key highlights follow: - What drives AdAlta’s “East to West” cellular immunotherapy strategy - How the “East to West” strategy will be AdAlta’s key driver of future pipeline growth and value creation - Recent progress made in executing the “East to West” strategy, including the signing of term sheets - How the value inherent in AdAlta’s fibrosis disease drug candidate AD-214 will be monetised ?? Tuesday, 11 February 2025 ?? Time 12:00 pm AEST / 9:00 am AWST ?? Register through:? https://lnkd.in/gj94FQqn ASX announcement:?https://lnkd.in/dZRPPjjd Investor Presentation:?https://lnkd.in/dtGbM3zR ? To arrange a meeting with management , please contact:?[email protected]